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Background: Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a
reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic
pharmacological immunomodulation could sensitize tumors to immune mediated cell death with an adoptive
T cell therapy.
Methods: The pan-HDAC inhibitor, LBH589, was combined with gp100 specific T cell immunotherapy in an
in vivo B16 melanoma model and in an in vivo non-tumor bearing model. Tumor regression, tumor specific
T cell function and phenotype, and serum cytokine levels were evaluated.
Results: Addition of LBH589 to an adoptive cell transfer therapy significantly decreased tumor burden while
sustaining systemic pro-inflammatory levels. Furthermore, LBH589 was able to enhance gp100 specific T cell
survival and significantly decrease T regulatory cell populations systemically and intratumorally. Even in the
absence of tumor, LBH589 was able to enhance the proliferation, retention, and polyfunctional status of tumor
specific T cells, suggesting its effects were T cell specific. In addition, LBH589 induced significantly higher levels
of the IL-2 receptor (CD25) and the co-stimulatory molecule OX-40 in T cells.
Conclusion: These results demonstrate that immunomodulation of adoptively transferred T cells by LBH589
provides a novel mechanism to increase in vivo antitumor efficacy of effector CD8 T cells.
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The adoptive transfer of tumor specific T cells is becom-
ing a viable treatment option for many patients with
solid tumors [1]. However, despite the ability to specif-
ically target tumors, adoptively transferred cells often
fail to survive and persist in vivo [2]. Their ability to
retain effector function diminishes quickly and often
transforms into a suppressive state, with an inability to
mobilize IFN-γ and other critical cellular functions
[3-5]. Many strategies have been employed to reverse* Correspondence: rprins@mednet.ucla.edu
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Strategies such as lymphodepletion prior to adoptive cell
transfer and high doses of IL-2 have been shown to signifi-
cantly increase retention and proliferation of adoptively
transferred T cells [6,7]. In addition, combining these
strategies with immunomodulation of the tumor itself
has shown the potential to increase responsiveness to
immunotherapy [8].
Histone deacetylase inhibitors (HDACis), such as vori-
nostat (SAHA) and romidepsin, are approved for the
treatment of cutaneous T-cell lymphomas. Such agents act
via multiple mechanisms, including cell cycle arrest and
activation of the intrinsic death pathway [9,10]. Acetyl-
ation and deacetylation of lysine residues on histone tails
and non-histone substrates controls a number of cellular
processes including the regulation of transcription,
transcription factor stability and cell survival. HistoneLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tylation of histone proteins and other non-histone protein
substrates [11]. Inhibition of histone deacetylases with
HDACis, such as vorinostat, can preferentially induce cell
cycle arrest, apoptosis, and differentiation in leukemic
malignancies and solid tumors [12]. More importantly,
HDACis have been shown to enhance tumor immunity
by upregulating the expression of major histocompati-
bility class (MHC) molecules, costimulatory molecules
and components involved in tumor necrosis factor
(TNF) superfamily signaling [13-17]. However, HDA-
Ci’s have also been shown to increase the function of T
regulatory cells and increase IDO immunosuppression
by dendritic cells [18-20]. These potentially contra-
dictory functions of HDACis in the context of tumor
immunity have complicated their inclusion in immuno-
therapy protocols.
In order to test whether an HDACi could synergize
with immunotherapy in an in vivo melanoma model, we
utilized LBH589 (Panobinostat) in combination with
T cell transfer therapy. LBH589 is a cinnamic hydroxa-
mic acid derivative with broad inhibitory activity of
class I, II, and IV HDACs in the low nanomolar range
[21]. It has shown clinical efficacy for the treatment
of multiple myeloma and Hodgkin’s lymphoma and
animal models in doses ranging from 10-100 mg/kg
[22,23]. However, whether LBH589 could similarly
enhance adoptive T cell transfer without generating a
potentially immunosuppressive milieu had yet to be
addressed. We utilized gp100 tumor associated antigen
specific Pmel T cell immunotherapy in an in vivo
melanoma model in order to address these concerns.
Adjuvant administration of LBH589 potently syner-
gized with adoptive cell transfer, and to our surprise,
created a highly pro-inflammatory environment that
could be measured by significant modulation of serum
cytokine levels. This was accompanied by a significant
expansion and enhancement of effector function, which
occurred in the presence or absence of tumor. Notably,
specific release of TNF following restimulation of Pmel
T cells and serum cytokine levels of TNF were significantly
increased and sustained over time. Taken together with an
increase in the T cell specific expression of the TNF super-
family receptor, OX-40, inclusion of LBH589 highlights
the potential new role of HDAC inhibitors in modulating
and sustaining in vivo T cell function.
Results
LBH589 synergizes with an adoptive cell transfer therapy
to reduce tumor burden
Significant controversy exists about whether HDACi toler-
ize or enhance anti-tumor immune responses. In addition,
the mechanisms by which HDACi alter immune respon-
siveness are not well understood. We previously reportedthat another HDACi similar to LBH589 (LAQ824) could
enhance ACT in a mouse model [24]. However, it was
unclear mechanistically how a pan-HDAC inhibitor
might synergize with adoptively transferred, tumor-
specific T cells in vivo. To test this new agent, mice with
10 day established B16 tumors were lymphodepleted with
500 cGy irradiation one day prior to adoptive transfer.
Treated groups then received 5 × 106 gp100-specific Pmel
T cells, supported by a gp10025-33 peptide pulsed dendritic
cell vaccination, and systemic IL-2 with or without
LBH589 (5 mg/kg). One week later, this was followed by a
second DC vaccination and IL-2 (Figure 1A). As a single
agent, LBH589 (5 mg/kg) did not decrease tumor bur-
den in comparison to untreated groups leading us to
conclude that this was an appropriate subtherapeutic
dose (p = 0.45). However, LBH589 in combination with
Pmel adoptive transfer therapy, showed significantly
greater control of tumor growth compared with Pmel
ACT alone (p = 0.019) (Figure 1B). Thus, LBH589 was
able to dramatically enhance the efficacy of a T cell
based therapy.
LBH589 alters and extends in vivo peripheral cytokine
production
Widely varied immunomodulatory effects of HDACi have
been reported in a number of different models [16,23,25].
The majority of these studies have highlighted the anti-
inflammatory properties of HDACi’s. In particular, it
is known that HDACi’s can dampen the anti-tumor
immune response, and reportedly involve the functional
enhancement and generation of T regulatory cells and
the production of IDO by dendritic cells. However,
given the therapeutic benefit observed in this in vivo
tumor model, we hypothesized that the administration
of an HDACi after the induction of lymphopenia and
adoptive cell transfer might alter the dynamics of the
systemic immune response differently. In order to assess
global changes in the inflammatory environment, we
quantified peripheral blood serum cytokine levels at 3 dis-
tinct time points following T cell ACT and DC vaccination
with, and without, LBH589 administration (Figure 2A).
The first sample was obtained one hour prior to DC
vaccination. The second and third serum samples were
then obtained 4 hours and 72 hours following vaccin-
ation respectively. A dramatic shift in the TH1 and pro-
inflammatory cytokine production was observed 4 hours
following DC vaccination (Figure 2B). This shift was
highlighted by a significant release of TNF and IL-2,
and a significant reduction in IL-5 and IL-10 in groups
treated with LBH589 and adoptive transfer compared with
groups that only received Pmel adoptive transfer. Further-
more, these significant shifts in pro-inflammatory cytokine
production were still noticeable 72 hours following vaccin-
ation. Notably, serum levels of IFN-γ ,TNF, and IL-10 were















































Figure 1 LBH589 in combination with an adoptive cell transfer therapy reduces tumor burden in a subcutaneous B16-F10 melanoma
model. A. Treatment schedule. B. Tumor growth measurements of the mean area of tumors in control mice treated with irradiation only, LBH589
following irradiation, Pmel T cell adoptive transfer, or Pmel T cell adoptive transfer therapy with LBH589 (n = 8 mice/group). Results are representative
of at least three independent experiments. Two-way ANOVA analyses were performed to determine statistical significance between treatment groups.
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adoptive transfer. These results are impressive considering
the serum half-life of TNF is approximately 10 minutes
[26]. Furthermore, the potency of this inflammatory
response 72 hours following vaccination is exemplified by
an increase in serum IL-10. Although we were unable to
determine the source of this IL-10 due to technical limita-
tions, we hypothesize that highly activated Pmel T cells
utilized this as a mechanism to control immunopathology.
These surprising results point towards a prolonged and
sustained global shift towards a pro-inflammatory envir-
onment in vivo.
Expansion of adoptively transferred cells and reduction of
T regulatory cells with LBH589 treatment
The previously reported anti-inflammatory properties of
HDAC inhibitors have generated little enthusiasm for
their concurrent use in cancer immunotherapeutic strat-
egies. However, with such extensive changes observed in
the cytokine environment, we investigated whether the
co-administration of LBH589 influenced the expansion
of Pmel T cells and other endogenous lymphocyte pop-
ulations. We quantified the percentages and absolute
numbers of adoptively transferred Pmel T cells and
endogenous regulatory T cell populations in mice with
established B16-F10 tumors (Figure 3A) We weresurprised to find that there was a significant increase
in the percentage of Pmel T cells (CD8+ Thy1.1+)
recovered from the spleen 3 days following DC vaccin-
ation (45% CD8 + Thy1.1+ with LBH589 vs. 14% for
placebo control; p = 0.0007) (Figure 3A). In contrast to
what has been reported, this expansion of adoptively
transferred T cells was accompanied by a decrease in
both the percentage and absolute number of endogenous
T regulatory cells (CD3+ CD4+ FoxP3+) recovered in the
spleen from 2.1% to 1.1% in mice treated with LBH589
(p = 0.039) (Figure 3A). This significantly altered the
tumor specific T cell to T regulatory cell ratio in the
periphery in mice treated with and without LBH589
respectively (121.9 vs. 8.1; p = 0.0064). Furthermore, this
was accompanied by a greater percentage of Pmel T
cells within the tumor when groups were treated with
LBH589 than treated without (39% vs. 11.7% respectively;
p = 0.0021), and an increased, though not significant,
density of tumor-infiltating Pmel T cells (Figure 3B).
Although the T regulatory cell frequency was low inside
these the tumors, the overwhelming tumor infiltrating
lymphocyte population enhanced the Pmel to T reg cell
ratio to 235.5 from 49.7 for mice treated with and without
LBH589, respectively (p = 0.06). This data suggests that
the result of HDACi coadministration can provide a pro-




Figure 2 Treatment with LBH589 alters the peripheral cytokine milieu of non-tumor bearing mice treated with LBH589. A. Treatment
scheme. Asterisks indicate timepoints in which serum was collected. B. Serum levels of cytokines in groups treated with and without LBH589.
Serum was taken one day prior to dendritic cell vaccination, and then four hours post vaccination. C. Serum cytokine levels of the same
treatment groups taken prior to dendritic cell revaccination on day 7 and then 72 hours following revaccination. Serum from at least 6 mice was
measured per cytokine. Student’s t-tests were performed to determine statistical significance between groups.
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sion and survival of tumor-specific T cells following adop-
tive transfer.
Enhanced T cell expansion with LBH589 is not dependent
on the presence of tumor
The ability of particular HDACi to immunosensitize tu-
mors has been documented and could explain the observed
synergism between ACT immunotherapy and LBH589
[13-16]. However, whether LBH589 directly influenced
T cell proliferation in the absence of tumor was still
unknown. In order to test whether LBH589 mediated its
effects independently from its effects on the tumor, we
adoptively transferred 5 × 106 Pmel T cells into lympho-
depleted, non-tumor bearing hosts. These cells were
again supported by a peptide pulsed DC vaccinationand IL-2, with or without LBH589. Ten days following
adoptive transfer, and 3 days following vaccination,
Pmel T cells constituted 81% of the splenic cellularity
(2.5 × 107 cells) in groups receiving LBH589, while Pmel
T cells only represented 19% (1.5 × 106 cells) without
LBH589 (p < 0.001) (Figure 4A). Furthermore, this expan-
sion was not limited to the spleen, but was also observed
in the percentage of Pmel T cells in the overall CD8 popu-
lation from peripheral blood (Figure 4B). This expansion
was the most dramatic following vaccination. In addition
to enhanced expansion, retention of Pmel cells also per-
sisted 21 days following adoptive transfer (11 days post
vaccination). Thus the, combination of an HDACi with a
T cell based immunotherapy was not immunosuppressive.
Instead, the coadministration of LBH589 resulted in in-
































































































































































Figure 3 Dramatic expansion and recovery of tumor specific T cells in vivo as a result of LBH589 treatment. A. Quantification of Pmel T
cells recovered from splenocytes collected 10 days after adoptive cell transfer according to the treatment scheme on Figure 1A. Representative
flow cytometry plots shown are derived from a lymphocyte gate followed by a live cell gate. Pmel: T reg ratios are determined by utilizing
absolute numbers of Pmel T cells (CD8+ Thy1.1+) to the absolute number of T reg cells (CD4+ CD25hi FoxP3+). B. Quantification of lymphocytes
within the tumor. Representative flow cytometry plots of lymphocytes isolated from subcutaneous B16 melanomas digested with collagenase
10 days following adoptive cell transfer. Dot plots shown are derived from lymphocyte and live cell gates. The Pmel: T reg ratio was calculated
using absolute number of Pmel T cells and T reg cells per mg of tumor. A and B dark circles indicate mice treated with adoptive cell transfer and
open squares indicate mice treated with adoptive cell transfer with LBH589 and each symbol represents one mouse. Each experiment described
has been conducted two times with similar results and included at least four mice per group. Student’s t-tests were performed to determine
statistical significance between groups.
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cells with LBH589
Realizing that LBH589 mediated such a profound effect
on the retention of adoptively transferred Pmel T cells,
we also addressed whether the function of these cellswas likewise enhanced. Optimal expansion of Pmel T
cells occurred in the days following revaccination, pro-
viding an ideal timeframe for us to assess their ability to
degranulate (CD107a+/LAMP-1+) and/or secrete the
cytokines IFN-γ and TNF. Lymphodepleted, non-tumor
A)
B)
Figure 4 Recovery and systemic expansion of Pmel T cells with LBH589 also occurs in the absence of tumor. A. Expansion of Pmel T cells
treated by the same scheme as shown in Figure 1A, but in non-tumor bearing irradiated hosts. Representative dot plots indicate the percentage
and absolute number of splenocytes that are Pmel T cells on day 10 following adoptive cell transfer. B. Analysis of Pmel T cell expansion in both
peripheral blood and spleen over time. Pmel T cell expansion in peripheral blood is expressed as the percentage of Pmel T cells in the overall
CD8 T cell population days 3, 10, and 21 days following adoptive cell transfer. Results described are representative of at least three experiments
with similar results. Student’s t-tests were performed to determine statistical significance between groups.
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Pmel T cells and supported with a dendritic cell vaccine
and IL-2 with or without LBH589. Ten days following
adoptive transfer, splenocytes from mice were obtained
and restimulated with gp10025-33 peptide for five hours.
During this time, the expression of CD107a was measured
in order to quantify the percentage of T cells undergo-
ing degranulation. In groups treated with LBH589, we
observed significant increases in Pmel T cell cytokine
secretion and degranulation. The percentage and MFI
of Pmel T cells secreting IFN-γ was significantly increased
in mice treated with LBH589 compared with those treated
without (88.9% vs. 74.1% respectively, p < 0.005) (Figure 5).
Furthermore, the percentage of Pmel T cells exhibiting
mobilization of the degranulation marker, CD107a, was
also increased in mice treated with LBH589 compared
with those treated without (92.5% vs 86.8% respectively,
p < 0.05) (Figure 5). The most dramatic difference ob-
served for LBH589 treated groups was more than a 2-fold
increase in the percentage of cells secreting TNF in com-
parison to those not treated (82.2% vs. 36.9% respectively,
p < 0.001) (Figure 5). When considering the number of
cells able to secrete both cytokines and demonstrate the
ability to degranulate, more than 70.9% of Pmel cells
simultaneously showed polyfunctionality when treated
with LBH589 in comparison to 30.2% in groups not
treated with LBH589 (p < 0.0001) (Figure 5). Furthermore,
this is in stark contrast to three days following adoptive
transfer when only 10% of untreated and 20% of LBH589treated Pmel T cells were able to secrete TNF (Additional
file 1: Figure S1). This demonstrated a significant enhance-
ment in the ability to respond to a peptide specific vaccin-
ation with elevated TNF secretion. For the first time, these
results demonstrate the ability of an HDAC inhibitor to
increase the in vivo polyfunctional capacity of adoptively
transferred CD8 T cells in vivo.
LBH589 enhances markers of activation on tumor specific
T cells
The TNF superfamily of ligands and receptors, as well as
TNF itself, are known to be modulated by HDACi’s in
numerous cancer cell lines [13,27-29]. Because our prior
results demonstrated significant enhancement of TNF
secretion by restimulated Pmel T cells, we investigated
whether LBH589 might influence the expression of the
TNF superfamily of ligands and receptors, as well as
other markers of T cell activation. We showed previously
that the high affinity IL-2 receptor α chain (CD25) was
important for proliferative and in vivo antitumor activity
of CD8 T cells [30]. In order to assess whether this was
also the case in mice treated with LBH589, we recovered
splenocytes from non-tumor bearing mice 10 days fol-
lowing adoptive cell transfer. Pmel T cells recovered
from groups treated with LBH589 showed a significantly
increased percentage of positively staining cells and MFI
of CD25 expression (Figure 6). At this time, we also
examined TNF family members normally expressed on
activated CD8 T cells. No significant changes in the
Figure 5 Functional enhancement of Pmel T cell cytokine production. Restimulation of Pmel T cell splenocytes with cognate gp10025-33
peptide ex vivo for five hours. Representative plots indicate splenocytes restimulated 10 days following adoptive cell transfer and are gated from
CD8+ Thy1.1+ Pmel T cells. Gates were set based on Pmel cells that lacked peptide stimulation for the 5 hour duration of the restimulation.
CD107a staining, as a marker for degranulation, was achieved by addition of CD107a antibody just immediately prior to the restimulation period.
Results described are representative of at least three experiments with similar results. Student’s t-tests were performed to determine statistical
significance between groups.
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detected (data not shown). However, OX-40 was signifi-
cantly upregulated on Pmel T cells following vaccination
in groups treated with LBH589. These results demonstrate
that utilization of LBH589 promotes a pro-inflammatory
environment and alters the T cell effector phenotype
through the expression of CD25 and OX-40.
Discussion
Our study addressed whether the adjunctive use of an
HDAC inhibitor could synergize with an adoptive cell
transfer therapy, without suppressing or compromising
a tumor specific effector T cell response. Utilization of
LBH589 dramatically enhanced the antitumor activity of
an adoptive T cell transfer therapy in a murine B16-F10
subcutaneous melanoma model. Inclusion of LBH589
together with adoptive T cell transfer induced significant
regression of established B16 melanoma tumors while
generating a systemic proinflammatory cytokine milieu,illustrated by the sustained release of IFN-γ and TNF.
Such enhanced antitumor activity was further exemplified
by the increased recovery of adoptively transferred Pmel
cells, both systemically and intratumorally, together
with a drastic reduction in the T regulatory cell popula-
tion. Surprisingly, enhanced Pmel T cell in vivo expan-
sion and effector function occurred even in the absence
of tumor in LBH589 treated groups. Phenotypically,
following adoptive transfer and treatment with LBH589,
Pmel T cells preferentially expressed high levels of the
TNF receptor family member, OX-40, and secreted high
levels of TNF following ex vivo restimulation. These
results highlight the significant antitumor and immuno-
modulatory activities of LBH589.
Our findings demonstrated that the adjunctive use of
LBH589 with adoptive T cell transfer significantly re-
duces T regulatory cell populations in the periphery and
within the tumor. This is significant when considering
the immunomodulatory properties of T reg cells in the
Figure 6 LBH589 increases expression of markers of T-cell activation and costimulation. Splenocytes from mice treated with and without
LBH589 were assayed for the expression of CD25, OX-40, CD40L and ten days after adoptive cell transfer. Representative plots are gated on CD8+ Thy1.1+
Pmel T cells. Each group contained 6 mice with similar data obtained in an independent experiment. Student’s t-tests were performed to determine
statistical significance between groups.
Lisiero et al. Journal for ImmunoTherapy of Cancer 2014, 2:8 Page 8 of 12
http://www.immunotherapyofcancer.org/content/2/1/8context of a tumor mass. Pre-clinical studies have dem-
onstrated that the infiltration of T reg cells specifically
within a tumor mass decreases effector T cell proliferation
and function [31]. Furthermore, pharmacological blockade
of a known T reg cell marker, CTLA-4, restored effector
T cell proliferation and synergized with a therapeutic
vaccine. In fact, the ability to modulate T regulatory cell
populations in vivo and significantly elevate the T effector
to T regulatory cell ratio can act as a positive predictive
factor for tumor rejection and promotes effector cell pro-
liferation and cytokine secretion [32]. Clinically, high
levels of peripheral T regulatory cell populations are nega-
tively associated with therapeutic responsiveness after
lymphodepletion and adoptive cell transfer in patients
[33]. Although this T regulatory cell population may not
be indicative of a tumor educated population, it may high-
light the overall status of immune responsiveness. Our
results, as well as evidence from both pre-clinical and clin-
ical studies, highlight the significance of T regulatory cellfunction in the context of immune based therapies. Thus,
the selective pharmacological modulation of T effector
function and T regulatory cell populations to significantly
increase anti-tumor activity makes LBH589 an extremely
attractive therapeutic that may abrogate the need for lym-
phodepletion prior to adoptive cell transfer. Future studies
are needed to address this hypothesis.
Our results also indicated an enhanced inflammatory
cytokine environment and state of T cell responsiveness.
In this light, we tested the ability of LBH589 to modulate
T cell function in non-tumor bearing hosts. We deter-
mined that the majority of immunological effects seen in
our treatment regimen were due to an overwhelming en-
hancement of T cell proliferation and function by LBH589,
even in the absence of tumor. Although one of the limi-
tations of our experimental design was that it did not
allow us to specifically distinguish whether LBH589 acts
directly on adoptively transferred T cells, dendritic cells,
or endogenous lymphocytes we hypothesize that in this
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on the activated T cells themselves. This is supported by
the fact that the lymphocytes in the spleen of LBH589
treated groups were composed primarily of Pmel CD8+
T cells, and a significantly lower percentage of CD4+ T
cells and CD4+ T regulatory cells. The enhancement of
T cell function we observed was dominated by a more
than 2 fold change in the tumor peptide (gp10025-33)
specific secretion of TNF ex vivo, mirroring the data
observed in serum cytokine levels. This is the first study
that demonstrates a pharmacological enhancement of
polyfunctional T cell status by an HDAC inhibitor. The
potency of this response was magnified if a third
dendritic cell vaccination was utilized at day 14 of this
treatment scheme. This resulted in a lethal cytokine
storm in a majority of mice treated with immunotherapy
and LBH589. From this data we concluded that only one
dendritic cell revaccination was necessary to mount an
effective anti-tumor response without adverse events. This
warrants further investigation into the molecular mecha-
nisms for HDACi mediated regulation of inflammatory
cytokines, and whether sub-optimal doses of IL-2 can
be utilized to support adoptively transferred cells. These
results are also surprising considering previous studies
have shown that LBH589 impairs the function and
phenotype of dendritic cells by downregulating co-
stimulatory molecules and repressing inflammatory
cytokine production [34]. Our own studies, which
utilize a peptide specific dendritic cell vaccine in com-
bination with adoptive T cell transfer, demonstrated
robust tumor specific T cell specific proliferation and
cytokine production following dendritic cell revaccin-
ation. Future studies will investigate whether LBH589
modulates dendritic cell function in the therapeutic
context of adoptive T cell transfers.
HDAC inhibitors have been shown to preferentially
regulate the expression of TNF superfamily members,
including TNF receptors, and TNF associated ligands
in tumors. The class I HDAC inhibitor, depsipeptide in-
creased the expression of TNF-related apoptosis-inducing
ligand (TRAIL) on chronic lymphocytic leukemia (CLL)
and acute lymphoblastic leukemia cell lines, sensitizing
them to death receptor-induced apoptosis [16]. Add-
itionally, inhibition of HDAC11 in Hodgkin lymphoma
increases the expression of OX-40 ligand and inhibits
the generation of IL-10 producing T regulatory cells
in vitro [29]. However, the modulation of TNF family
members by HDAC inhibitors in CD8+ T cells has not
been previously demonstrated. In this study, we demon-
strated an increase in the specific expression of TNF and
TNF superfamily member, OX-40, by tumor-specific T
cells. TNF has been shown to be crucial for the priming
and effector function of CD8 T cells during an antitu-
mor immune response [35,36]. This is especiallysignificant considering that proper costimulation and
cytokine support for effective T cell responses is severely
lacking during tumor surveillance. OX-40 is a critical co-
stimulatory molecule that is necessary for effector function,
survival, and memory generation [35,37]. In vivo, OX-40
agonistic antibodies potentiate CD8 T cell memory gener-
ation and antitumor activity [38-40]. Therefore, inclusion of
LBH589 in current adoptive cell transfer protocols could
potentially enhance the anti-tumor activity of T cells by
providing in vivo co-stimulation through OX-40. Taken
together with the increased expression of the high affin-
ity IL-2 receptor, CD25, we believe that increased
expression of OX-40 imparts a highly activated pheno-
type to CD8+ T cells that allows them to compete for
proliferative cytokines (IL-2) and co-stimulation through
OX-40. We believe that LBH589 may specifically modu-
late the proliferation, retention, and responsiveness of
CD8 T cells.
We have demonstrated that LBH589 potentiates the
function of CD8 T cells, and this occurs in the pres-
ence and absence of tumor. We demonstrated that an
HDAC inhibitor has the potential to sensitize tumor
specific cells to peptide specific vaccination and acqui-
sition of full T cell effector function, by increasing
peptide specific secretion of TNF, expression of the
co-stimulatory receptor, OX-40, and expression of the
IL-2 high affinity receptor, CD25. Further investiga-
tions need to be conducted in order to determine
whether LBH589 directly modulates histone acetyl-
ation in CD8+ T cells and transcriptionally regulates
T cell effector function and expression of TNF super-
family members. Furthermore, although the HDAC
target(s) of LBH589 inhibition responsible for these
immunomodulatory activities is unclear, this study
provides additional mechanistic insight into the ability
of HDACs to specifically regulate T cell function and
anti-tumor activity. Our results highlight LBH589 as a
safe and effective adjuvant to regulate the proliferation
and function of adoptively transferred tumor specific
T cells, and potentially warrants its inclusion in future
ACT human clinical trials.
Conclusions
The histone deacetylase inhibitor, LBH589, synergizes
with adoptive T cell transfer therapy and helps mediate
potent antitumor activity in an in vivo melanoma
model. In this immunotherapeutic context, LBH589
enhanced the retention of polyfunctional tumor spe-
cific T cells, promoted systemic cytokine responses,
and increased the effector to regulatory T cell ratio.
These results demonstrate the ability of a pan histone
deacetylase inhibitor to effectively modulate the antitu-
mor response and warrants further studies for future
clinical use.
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Animals and cell lines
All mice were bred and kept under defined-flora pathogen-
free conditions at the Association for Assessment and
Accreditation of Laboratory Animal Care-approved ani-
mal facility of the Division of Experimental Radiation
Oncology at the University of California Los Angeles.
Mice were handled in accordance with the University of
California Los Angeles animal care policy and approved
animal protocols. The B16-F10 murine melanoma cell
line was obtained from American Type Culture Collec-
tion (Rockville, MD).
Tumor implantation and lymphodepletion
For studies analyzing tumor growth over time in an
in vivo melanoma model, C57BL/6 mice (6-12 weeks of
age) were implanted subcutaneously in the lower left
flank with 2 × 105 B16-F10 melanoma cells and allowed
to establish for 10 days. For studies analyzing tumor
infiltrating lymphocytes, 2.5 × 105 B16-F10 melanoma
cells were implanted in the same location and allowed to
establish for 10 days.
One day prior to adoptive T-cell transfer, lymphopenia
was induced by 500 cGy total body irradiation.
Adoptive T cell transfer and dendritic cell vaccination
Pmel-1 T cells and bone marrow derived dendritic cells
were generated as previously described [30]. In brief,
naïve Pmel-1 splenocytes were activated with human
gp10025-33 peptide (NH2-KVPRNQDWL-OH, 1 ug/ml;
Biosynthesis, Lewisville, TX) and 100 IU/ml human
IL-2 (National Cancer Institute Preclinical Repository,
Developmental Therapeutics Program) for 72 hours
[30]. These cells were then re-cultured for an additional
48 hours in 100 IU/ml IL-2 without hgp100. Pmel-1 T-cells
(5 × 106) were injected i.v. in 0.1 ml PBS.
Bone marrow derived dendritic cells were generated as
previously described [30]. Bone marrow cells from the
femurs and tibias of 2 Bl/6 mice were initially cultured
overnight in a petri dish in RPMI 1640 supplemented
with 10% FBS and pencillin/streptomycin. The next day,
non-adherent cells were collected and washed twice with
media and re-cultured in 50 ml of fresh media contain-
ing 2 ng/ml recombinant murine GM-CSF and 10 ng/ml
recombinant murine IL-4 (Peprotech). Cells were then
plated at 1 ml per well in 24 well plates and cultured for
3 days. On the third day, 0.5 ml of media was removed
and 1 ml of new media containing 10 ng/ml IL-4 and
2 ng/ml GM-CSF was added. On the 7th day, cells were
harvested by using a syringe plunger to scrape cells from
the bottom of each well. Once harvested, dendritic cells
were pulsed with human gp10025–33 peptide at a concen-
tration of 10 μM for 90 min at room temperature.
Approximately 5 × 105 were injected subcutaneously atfour sites on the back [41]. IL-2 (5 × 105 IU) was adminis-
tered in 500 ul and given as an intraperitoneal injection.
LBH589 (a kind gift from Novartis) was given at a dose of
5 mg/kg and administered at the same time as IL-2.
Ex vivo Pmel-1 T cell stimulation and intracellular FACS
staining
After the indicated time periods following adoptive T cell
transfer, splenocytes were enumerated and restimulated
with or without hgp10025-33 peptide. GolgiPlug protein
transport inhibitor (BD Biosciences) and allophycocya
nin-conjugated anti-CD107a mAb (2 ug, clone 1D4B; BD
Biosciences) were added to each well containing T cells.
Cells were stimulated at 37°C for 0, 1, 2, or 5 hours.
After each time period, cells were placed on ice in the
dark until all cells could be stained at the same time.
Cells were washed with PBS containing 2% FBS and
stained with CD8 mAb, Thy1.1 mAb, and a fluorescent
cell viability stain (Live/Dead, Invitrogen) on ice. Cells
were fixed and permeabilized with intracellular fixation
and permeabilization buffer set from eBioscience. Intra-
cellular staining was then completed by staining with
IFN-γ, TNF-α and IL-2 mAbs on ice in the dark.
Flow cytometry and mAbs
Spleens and tumors were harvested from mice after
adoptive transfer. Spleens were passed through 70 um
cell strainers and lymphocytes were obtained after hypo-
tonic lysis. Approximately 1 × 106 were used for each
staining. To determine the number of tumor-infiltrating
lymphocytes (TILs), tumors were weighed and minced
with a scalpel. The tumor was then digested in collage-
nase with DNase for 2 hours on a rotator. Small mono-
nuclear cells within the tumor were enumerated by
trypan blue exclusion, with approximately 1 × 106 lym-
phocytes used for staining. TILs were calculated by de-
termining the absolute number of CD8+ Thy1.1+ cells
per milligram of tumor.
Fluorochrome conjugated Abs to CD4 (clone RM4-5),
CD8 (clones 5H10 and 53-6.7), CD107a (clone 1D4B),
IFN-γ (clone XMG1.2), TNF-α (clone MP6-XT22) and
IL-2 (clone JES6-5H4) were obtained from BD Biosci-
ences or Biolegend. Fluorochrome conjugated Abs to
Thy1.1 (clone HIS51) and FoxP3 (clone FJK-16 s) were
obtained from eBioscience. For intracellular cytokine
staining, cells were washed with PBS containing 2%
FBS and subsequently stained with surface markers.
After extracellular staining, cells were fixed with Fixation
Buffer (eBioscience) and permeabilized with Permeabiliza-
tion Buffer (eBioscience). Intracellular staining was com-
pleted in Permeabilization Buffer on ice in the dark. Cells
were stored at 4°C until analysis.
All FACS analysis was performed with the use of an
LSRII (BD Biosciences). Gates were set based on samples
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cells, as determined by negative staining with a dead cell
stain (Live/Dead Fixable Near-IR Dead Cell Stain Kit,
Invitrogen), were included in subsequent analyses. Data
were analyzed using FlowJo software (Treestar).
Assessment of serum cytokine levels
Serial blood measurements were obtained by retro-
orbital sinus collection at the time points indicated.
Collected blood was allowed to clot for 30 minutes be-
fore centrifugation for 10 minutes at 1000 × g. Serum
was removed immediately and stored at -20°C until
utilized. Cytokine serum levels were assayed with a
Milliplex MAP Mouse Cytokine Magnetic Bead Panel
(Millipore) and analysis was performed in the Center
for AIDS Research ImmunoBioSpot Core Facility that
is supported by National Institutes of Health awards
CA-16042 and AI-28697, and by the UCLA AIDS
Institute.
Additional file
Additional file 1: Figure S1. Functional enhancement of Pmel T cell
cytokine production. A. Restimulation of Pmel T cell splenocytes with
cognate gp10025-33 peptide ex vivo for five hours. Representative plots
indicate splenocytes restimulated 3 days following adoptive cell transfer
and are gated from CD8+ Thy1.1+ Pmel T cells. Gates were set based on
Pmel cells that lacked peptide stimulation for the 5 hour duration of the
restimulation.
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